Venus Remedies Limited (IN:VENUSREM)
:VENUSREM
Want to see IN:VENUSREM full AI Analyst Report?
VENUSREM Stock Chart & Stats
₹782.25
-₹3.85(-1.26%)
At close: 4:00 PM EST
₹782.25
-₹3.85(-1.26%)
Day’s Range― - ―
52-Week Range₹295.00 - ₹1,119.00
Previous CloseN/A
Volume28.34K
Average Volume (3M)2.33K
Market Cap
₹12.68B
Enterprise Value₹12.12B
Total Cash (Recent Filing)₹2.36B
Total Debt (Recent Filing)₹143.80M
Price to Earnings (P/E)10.0
Beta0.67
Next Earnings
Jun 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)19.14
Shares Outstanding13,366,988
10 Day Avg. Volume2,529
30 Day Avg. Volume2,330
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)0.75
Price to Sales (P/S)0.65
P/FCF Ratio5.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)39.9
Revenue Forecast (FY)₹828.20M
Bulls Say, Bears Say
Bulls Say
Cash GenerationSustained positive free cash flow after capital expenditures provides durable internal funding for regulatory filings, manufacturing capacity and working capital. This reduces dependence on external financing, supports opportunistic investment or M&A, and enhances resilience across pharma development cycles.
Balance-sheet StrengthA strong equity position and low financial leverage lower the risk of distress and preserve borrowing capacity. For a capital-intensive drug manufacturer, this balance-sheet strength enables sustained investment in plants, registrations and product approvals without materially jeopardizing liquidity or credit flexibility.
Margin And Profitability ImprovementImproving gross and net margins and solid EBIT/EBITDA indicate durable cost control, favorable product mix or pricing power. Sustainable margins underpin internal financing for R&D and expansion, improve cash conversion, and provide buffers versus competitive pricing pressures in generics and hospital segments.
Bears Say
Moderate Revenue GrowthSub-10% reported top-line growth suggests modest organic expansion relative to high-growth pharma peers. Over the medium term, limited revenue acceleration can constrain scale economics and force reliance on margin expansion, exports or acquisitions to materially lift earnings and market position.
Product And Channel ConcentrationConcentration in anti-infectives and tender-driven hospital portfolios creates lumpy demand and intense price competition. Reliance on institutional tenders increases revenue and margin volatility and limits predictable, diversified growth unless the company broadens therapeutic scope or geographic footprint.
Limited Public Strategic Catalysts/visibilityAbsence of announced partnerships, regulatory milestones or forward guidance reduces visibility into medium-term growth drivers. That opacity makes it harder to assess sustainable catalysts for revenue diversification or capacity expansion and may slow confidence in strategic execution over coming quarters.
Venus Remedies Limited News
VENUSREM FAQ
What was Venus Remedies Limited’s price range in the past 12 months?
Venus Remedies Limited lowest stock price was ₹295.00 and its highest was ₹1119.00 in the past 12 months.
What is Venus Remedies Limited’s market cap?
Venus Remedies Limited’s market cap is ₹12.68B.
When is Venus Remedies Limited’s upcoming earnings report date?
Venus Remedies Limited’s upcoming earnings report date is Jun 03, 2026 which is in 35 days.
How were Venus Remedies Limited’s earnings last quarter?
Venus Remedies Limited released its earnings results on Jan 29, 2026. The company reported ₹19.137 earnings per share for the quarter, beating the consensus estimate of N/A by ₹19.137.
Is Venus Remedies Limited overvalued?
According to Wall Street analysts Venus Remedies Limited’s price is currently Overvalued.
Does Venus Remedies Limited pay dividends?
Venus Remedies Limited pays a Annually dividend of ₹3 which represents an annual dividend yield of N/A. See more information on Venus Remedies Limited dividends here
What is Venus Remedies Limited’s EPS estimate?
Venus Remedies Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Venus Remedies Limited have?
Venus Remedies Limited has 13,366,988 shares outstanding.
What happened to Venus Remedies Limited’s price movement after its last earnings report?
Venus Remedies Limited reported an EPS of ₹19.137 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 3.237%.
Which hedge fund is a major shareholder of Venus Remedies Limited?
Currently, no hedge funds are holding shares in IN:VENUSREM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Venus Remedies Limited
Venus Remedies Limited develops and markets pharmaceutical products in India and internationally. The company offers its products in various therapeutic areas, such as analgesic, analgesic and antipyretic, anti-diabetic, antibiotic, anticoagulant, cardiac, disinfectant and antiseptic, gastro therapy, hand sanitizers, hormones, iron supplements, neurology, oncology, pain management, respiratory, skin and wound care, stress reliever, urology, and vitamins/minerals/nutrients, as well as antimicrobial resistance products. It also provides disinfectants; and a portfolio of herbal products. Venus Remedies Limited was incorporated in 1989 and is headquartered in Panchkula, India.
Technical Analysis
Ind-Swift Laboratories Ltd.
―
Kilitch Drugs (India) Limited
―
Medicamen Biotech Limited
―
Nectar Lifesciences Ltd.
―
Zim Laboratories Ltd.
―